Oncotarget

Research Papers:

A GLO10 score for the prediction of prognosis in high grade gliomas

Feng Chen, Peng Peng, Yi Zhou, Zhen-Yu Yang, Hai-Quan Zhang, Xiang-Sheng Ao, Da-Quan Zhou _ and Chun-Xiang Xiang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:70899-70906. https://doi.org/10.18632/oncotarget.20195

Metrics: PDF 838 views  |   HTML 1593 views  |   ?  


Abstract

Feng Chen1,*, Peng Peng1,*, Yi Zhou1, Zhen-Yu Yang1, Hai-Quan Zhang1, Xiang-Sheng Ao1, Da-Quan Zhou1 and Chun-Xiang Xiang2

1Department of Neurosurgery, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, Hubei 441021, P. R. China

2Department of Pathology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, Hubei 441021, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Da-Quan Zhou, email: [email protected]

Chun-Xiang Xiang, email: [email protected]

Keywords: glioblastoma, prognosis, biomarker, DNA microarray, LASSO

Received: February 04, 2017    Accepted: July 24, 2017    Published: August 10, 2017

ABSTRACT

Gliomas are the most common lethal brain tumours and remain great heterogeneity in terms of histopathology and clinical outcomes. Among them, glioblastomas are the most aggressive tumours that lead to a median of less than one-year survival in patients. Despite the little improvement of in diagnosis and treatments for last decades, there is an urgent need for prognostic markers to distinguish high- and low-risk patients before treatment. Here, we generated a list of genes associated with glioblastoma progressions and then performed a comprehensive statistical modelling strategy to derive a 10-gene (GLO10) score from genome wide expression profiles of a large glioblastoma cohort (n=844). Our study demonstrated that the GLO10 score could successfully distinguish high- and low-risk patients with glioblastomas regardless their traditional pathological factors. Validated in four independent cohorts, the utility of GLO10 score could provide clinicians a robust prognostic prediction tool to assess risk levels upfront treatments.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20195